Aims: The aim of this study was to assess how quickly and effectively duloxetine improves energy compared with placebo in patients with major depressive disorder (MDD). Methods: Data from 10 randomised, double-blind, placebo-controlled clinical trials examining duloxetine (40-60 mg/day) vs. placebo in patients diagnosed with MDD were analysed. Change from baseline at Week 1 through Week 8 in Hamilton Depression Rating Scale (HAM-D) retardation subscale score (Item 1 -depressed mood, Item 7 -work and activities, Item 8 -retardation and Item 14 -genital symptoms) was assessed with mixed model repeated measures analysis. Positive predictive values and negative predictive values were calculated for predictor analysis. We demonstrated that treatment with duloxetine, quickly and with increasing magnitude over treatment time, improves low energy symptoms. As early as 1 week after starting treatment with duloxetine, improvement of low energy may serve as a predictor of remission at end-point. Conclusions: Treatment with duloxetine improves energy in patients with MDD and early response in retardation may serve as a modest predictor of remission at end-point.
Introduction
Symptoms associated with major depressive disorder (MDD) are very diverse, and include depressed mood, weight changes, insomnia or hypersomnia, psychomotor agitation, fatigue or loss of energy, feelings of worthlessness, diminished ability to concentrate and recurrent thoughts of death (1) . Prevalence of fatigue and low energy is high among patients with MDD, and these symptoms are clinically relevant for patients seeking treatment for MDD (2, 3) . In a previous study, performed by general practitioners, fatigue was reported to be one of the most common symptoms (93.6%) in patients with major depression (4) . In addition, a pan-European study found that the most common symptoms experienced by patients with depression were sleep problems (63%), tiredness (73%) and low mood (76%) (5) . Fatigue often does not respond well to treatment with antidepressants, even in patients classified as treatment responders, and fatigue often persists as a symptom of depression between depressive episodes (6, 7) . Clinical studies assessing energy levels in patients with MDD commonly refer to low energy as tiredness, fatigue, loss of energy or reduced energy levels (3) (4) (5) . A tool used in clinical studies to assess energy levels is the Hamilton Depression Rating Scale (HAM-D) retardation subscale (8) score (consisting of four HAM-D items: Item 1 -depressed mood; Item 7 -work and activities; Item 8 -retardation and Item 14 -genital symptoms; Items 1, 7 and 8 are also contained in the Maier subscale, which focuses on the core emotional symptoms of depression). Failure to treat residual symptoms of depression, such as fatigue and low energy, impedes the ability of patients to achieve remission (2) .
Antidepressants that increase noradrenergic and dopaminergic effects have demonstrated superiority over serotonergic antidepressants in the treatment of depressive symptoms such as fatigue and loss of energy (9) . Duloxetine is a potent inhibitor of serotonin (5-hydroxytryptamine) and norepinephrine reuptake, and is balanced in its affinity of binding to serotonin and norepinephrine transporter sites (10, 11) . Acute administration of duloxetine increases extracellular monoamine levels (12) , thereby, enhancing monoaminergic tone. Duloxetine has demonstrated efficacy in the acute treatment of MDD in randomised, double-blind, placebo-controlled trials (13) (14) (15) and is known to improve retardation symptoms (16) . However, the magnitude of improvement of low energy and retardation after treatment with duloxetine in patients with MDD has not been sufficiently assessed. In addition, while Katz et al. examined the predictive value of improvement of low energy after 2 weeks of treatment with duloxetine for the patients' outcome at end-point (17) , it is unknown if improvement of energy at earlier time points (e.g. 1 week of treatment) has predictive value for patient outcome. Finally, it is unknown if the effects of duloxetine differ between patients with high and low levels of retardation at baseline.
This study has two main objectives -to assess whether duloxetine is associated with faster and greater improvements of energy in patients with MDD compared with placebo, and to evaluate whether early improvement in energy could be an indicator for achieving response and/or remission, and, thus, impacts the clinical prognosis of MDD. An additional exploratory objective was to assess differences in the effects of duloxetine on retardation symptoms between patients with high levels of retardation at baseline, compared with patients with low levels of retardation at baseline.
Methods
We conducted a patient-level pooled analysis of data from 10 clinical trials comparing duloxetine 40-60 mg/day (doses approved in Japan) and placebo in adult patients with MDD to assess whether low energy in patients with MDD responds to treatment with duloxetine as assessed with the HAM-D retardation subscale score.
The protocols for the individual studies were reviewed and approved by the applicable organizational ethical review boards. The patients provided written informed consent before undergoing any study procedures, and the studies were conducted in accordance with the ethical principles of the Declaration of Helsinki, Good Clinical Practice and applicable laws and regulations.
Data sources
We conducted post hoc analyses of data from 10 randomised, double-blind, placebo-controlled clinical trials of duloxetine (HMAQa, HMAQb, HMATa, HMATb, HMBHa, HMBHb, HMCB, HMCR, HMFA, HMFS) (13, 14, (18) (19) (20) (21) (22) (23) (24) (25) (Table 1) in patients diagnosed with MDD by using the Diagnostic and Statistical Manual of Mental Disorders. The studies were included in an integrated database, which allowed patient-level analysis. Included in the analyses were all studies in the database that met the following criteria: patients diagnosed with MDD, acute placebo-controlled (with at least one duloxetine treatment arm receiving a dose approved in Japan, 40-60 mg/day) and depressive symptoms were assessed by using the HAM-D (26) so data from the HAM-D retardation subscale score were available. Only data from the acute treatment phases of the studies throughout Week 8 (up to Day 70) were included in the analyses. No studies with less than 6 weeks of study duration, and no maintenance treatment phases were included in the analyses; additionally, for the patient selection within the selected studies, data from patients who received duloxetine > 60 mg/day were excluded to align with the dose approved in Japan. Study protocols permitted minimum anxiolytic use by the patients; patients with psychosis, other psychiatric diseases and dementia were excluded from study participation.
Efficacy assessment
To evaluate how quickly changes in energy levels occur, change on the HAM-D retardation subscale (8) To confirm if duloxetine's effect on energy sustains over time, we examined the time to first onset of sustained improvement of energy using KaplanMeier analysis. Previous studies showed a 20% early improvement in depressive symptoms as clinically relevant and predictive of further improvement (17, 27) . Therefore, we chose 20% reduction in HAM-D retardation subscale scores as an indication of improvement in energy, and examined if duloxetine separates from placebo on this measure. First onset of sustained improvement of energy was defined as the first time point at which the HAM-D retardation subscale score was reduced by ≥ 20% and this reduction was maintained throughout Day 70 of treatment.
To investigate the clinical implications of this early improvement in energy on patients, we evaluated whether early improvement in energy (at Week 1, 2 or 4) could predict response/remission at Week 8 [missing data at Week 8 were imputed using lastobservation-carried-forward (LOCF) analysis method]. Early improvement of energy was defined as a ≥ 20% decrease on the HAM-D retardation subscale according to Katz et al. (17) , and, although they evaluated the predictive value of early improvement only at Week 2, we evaluated the predictive value of early improvement at Weeks 1, 2 and 4. For end-point assessment, response was defined as HAM-D total score ≥ 50% decrease from baseline, and remission was defined as HAM-D total score ≤ 7.
In addition, subgroup analyses were performed by using baseline HAM-D retardation subscale scores to categorise patients into two subgroups: patients with high levels of retardation at baseline (HAM-D retardation subscale score ≥ 8 at baseline) and patients with low levels of retardation at baseline (HAM-D retardation subscale score < 8 at baseline), as previously implemented by Judge et al. (3) .
Statistical analyses
Based on intent-to-treat principles, all randomised patients assigned to duloxetine (40-60 mg/day) or placebo with baseline and at least one postbaseline HAM-D assessment were included in the analyses.
For treatment comparison, v 2 test, mixed model repeated measures (MMRM) or Cox proportional hazard model were used based on the variable type. The MMRM model included study, treatment, visit, baseline, treatment 9 visit and baseline 9 visit as fixed effects. The Cox proportional hazard model included study and treatment. A Kaplan-Meier survival curve was also created. All tests were conducted by using a significance level of 5%. For the predictor analysis, positive predictive values (PPVs) and negative predictive values (NPVs) were calculated. The PPV expresses the proportion of patients who achieved response or remission among all patients who experienced early improvement of energy. The NPV expresses the proportion of patients who did not achieve response or remission among all patients who did not experience early improvement of energy.
For the subgroup analyses, analysis of covariance (ANCOVA) with treatment, level of baseline fatigue, their interaction, study and baseline were used. Interaction was evaluated by using a significance level of 10%.
All analyses were post hoc and no adjustments for multiplicity were made.
Results

Patient baseline characteristics
Of 2761 patients who were randomly assigned to treatment, 1555 patients received treatment with duloxetine, and 1206 patients received placebo. Most patients were female (64.3%) and Caucasian (76.3%). Patients had a mean [standard deviation (SD)] age of 46.2 (15.9) years and a mean (SD) HAM-D total score of 20.3 (5.19) at baseline. Gender and ethnicity distributions, age and baseline illness characteristics were similar between duloxetine and placebo groups (Table 2) .
Patient disposition
Fewer patients receiving treatment with duloxetine discontinued the studies early compared with placebo (duloxetine: 23.9% vs. placebo: 28.5%; P = 0.005). While early discontinuations due to lack of efficacy were more frequently observed in the placebo group compared with treatment with duloxetine (duloxetine: 3.2% vs. placebo: 9.9%; p < 0.0001), the opposite was true for early discontinuations because of adverse events (duloxetine: 8.1% vs. placebo: 4.6%; p = 0.003) ( Table 3) .
Changes in HAM-D retardation subscale scores and individual retardation subscale item scores
Patients treated with duloxetine experienced statistically significantly greater reductions in HAM-D retardation subscale scores compared with placebo beginning at Week 1 of treatment throughout Week 8 ( Figure 1 ). The observed differences in score changes between duloxetine and placebo groups became gradually bigger from Week 1 to Week 8 with increasing effect sizes (0.079-0.303).
Among individual HAM-D items that are included in the retardation subscale, changes in the course of treatment and effect sizes differed. However, at Week 8, treatment with duloxetine was consistently associated with statistically significantly greater score reductions compared with placebo for all individual items (Figure 2A-D) .
First onset of sustained 20% improvement of energy
The median [95% confidence interval (CI)] time to first onset of sustained improvement of energy was 28.0 days (26.0, 28.0) for patients receiving duloxetine and 42.0 days (36.0, 49.0) for patients receiving placebo. Treatment with duloxetine was associated with a significantly faster onset of efficacy compared with placebo with a hazard ratio (95% CI) of 1.4 (1.3, 1.5) (Figure 3 ).
Predictor analysis
Of the patients receiving treatment with duloxetine, 43.8% (681/1555) achieved response and 31.9% (496/1555) achieved remission at Week 8. To explore the predictive value of early improvement of energy for response and remission at Week 8, a predictor analysis was performed ( (Table 4) .
HAM-D retardation subscale score and 17-item HAM-D total score changes in patients with high vs. low retardation
To evaluate the effect of baseline energy levels on patient outcome at Week 8, patients were grouped by baseline retardation subscale scores in two subgroups: patients with high retardation (HAM-D retardation subscale score ≥ 8 at baseline) and patients with low retardation (HAM-D retardation subscale score < 8 at baseline). A significant interaction (significance level: 0.1) was observed between treatment and baseline retardation levels for baseline through week 8 change on the HAM-D retardation subscale score ( Figure 4A ). When comparing mean change from baseline in HAM-D retardation subscale scores between the two subgroups in patients receiving placebo, patients with high retardation seemed to show smaller overall decreases compared with patients with low retardation. When comparing mean change from baseline between the two subgroups in patients receiving duloxetine, patients with Figure 4A ). When examining mean changes from baseline within both retardation subgroups, patients treated with duloxetine showed statistically significantly greater decreases compared with placebo ( Figure 4A ). Similar trends were observed for changes on the HAM-D total score from baseline to week 8 ( Figure 4B ).
Discussion
The analyses presented here, based on a big sample size drawing data from 10 clinical trials, provide evidence that duloxetine improves low energy symptoms (as assessed with the HAM-D retardation subscale score) quicker and to a greater degree than placebo in patients with MDD. This observation is consistent with Shelton et al., who demonstrated that duloxetine improves scores on the HAM-D retardation subscale starting after 1-2 weeks of treatment (16) . This study similarly observed improvement of HAM-D retardation subscale scores after 1 week of treatment with duloxetine and efficacy was maintained throughout Week 8, with increasing magnitude over time. In addition, the results of the Kaplan-Meier analysis confirmed that the initial energy improvement, which is clinically relevant, sustains over time.
Early improvement in energy levels that was observed in this study re-emphasises the role of noradrenergic action in the treatment of MDD. Previously, the noradrenergic neurotransmitter system has been reported to be primarily associated with arousal and activity (28) , and Katz et al. demonstrated early improvement in psychomotor retardation after treatment with the selective norepinephrine reuptake inhibitor (SNRI) desipramine (17) . Singh et al. demonstrated greater reduction in retardation symptoms after treatment with venflafaxine, a SNRI, compared with treatment with escitalopram, a selective serotonin reuptake inhibitor (SSRI) (29) . A pooled analysis by Papakostas et al. indicated that patients with MDD displaying prominent symptoms of fatigue/sleepiness may benefit more from treatment with buporprion, a norepinephrine-dopamine reuptake inhibitor, compared with treatment with SSRI (30) . Here, we demonstrate that the serotonin and norepinephrine reuptake inhibitor, duloxetine, improves low energy starting at Week 1 throughout Week 8, reinforcing and confirming the earlier observations. At Week 8, the effect size for improvement on the HAM-D retardation subscale was 0.3 when comparing duloxetine with placebo, consistent with previous observations by Shelton et al. (16) . Among the four items constituting the HAM-D retardation subscale, changes in response to treatment were more pronounced for Items 1 and 7, while Items 8 and 14 presented smaller changes.
The predictor analysis demonstrates the clinical meaning of early improvement. In the current analyses, patients had a 32% likelihood of achieving remission at the initiation of treatment with duloxetine; however, if early improvement after 1 week was (PPV = 55.4% and NPV = 80.4% for achieving sustained remission) (17) . Our data further demonstrate that the predictive value after 1 week is similar to that after 2 weeks. Thus, improvement of energy after 1 week may be a modest but substantially better predictor than baseline for remission at end-point. 
